Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 631
- Registration Number
- NCT02340221
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria
🇧🇬Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02333370
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02291913
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Phase II Study of Everolimus Beyond Progression
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT02269670
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT02219789
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 333
- Registration Number
- NCT02216786
- Locations
- 🇬🇪
Tbilisi Cancer Center, Tbilisi, Georgia
🇵🇹Ipo Porto, Porto, Portugal
🇭🇺Bacs-Kiskun County Hospital, Kalocsa, Hungary
Endocrine Response in Women With Invasive Lobular Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Priscilla McAuliffe
- Target Recruit Count
- 201
- Registration Number
- NCT02206984
- Locations
- 🇺🇸
Univ. of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸ALBERT EINSTEIN COLLEGE OF MEDICINE Montefiore Medical Center, Bronx, New York, United States
🇺🇸Josh Plassmeyer, Pittsburgh, Pennsylvania, United States
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Fudan University
- Registration Number
- NCT02140437
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 37
- Registration Number
- NCT02137837
- Locations
- 🇺🇸
St. Patrick Hospital, Missoula, Montana, United States
🇺🇸Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
🇺🇸Clackamas Radiation Oncology Center, Clackamas, Oregon, United States
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 22
- Registration Number
- NCT02137083
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.